Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Sinovac Biotech Ltd. Stories

2012-08-06 02:25:45

BEIJING, Aug. 6, 2012 /PRNewswire-Asia -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2012, before market on Wednesday, August 15, 2012. The Company will host a conference call on Wednesday, August 15, 2012, at 8:00 a.m. EDT (August 15, 2012, at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on...

2012-07-16 02:24:03

BEIJING, July 16, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2012 Annual Meeting of Shareholders on Wednesday, August 22, 2012 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple Street, St. John's, Antigua. All shareholders of record as of July 5, 2012 will be eligible to vote and...

2012-06-25 02:26:04

BEIJING, June 25, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today provided an update on its Phase III clinical trial progress and commercialization preparation for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD). EV71 Clinical Trial The double-blinded, randomized, placebo controlled Phase III trial is being conducted at three sites across China's...

2012-06-18 02:27:09

BEIJING, June 18, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that management is scheduled to present at the 5th Annual BioPharma China Convention 2012, to be held June 20 and 21 at the Beijing Marriot Hotel Northeast in Beijing, China. Bringing together more than 300 global biopharmaceutical professionals, the 2012 convention will focus on opportunities for greater achievements in novel vaccines and...

2012-06-11 02:25:25

BEIJING, June 11, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced a positive SFDA inspection of the three clinical trial sites being used in the Company's Phase III study of its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD). In May 2012, an expert from the Center for Drug Evaluation within the State Food and Drug Administration (SFDA) completed an...

2012-05-15 02:28:13

BEIJING, May 15, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012. Financial Highlights (year-over-year comparisons to first quarter 2011) Sales increased 30.3% to $6.0 million, with Bilive vaccines sales up 92.4%. Gross margin was 62.2%, which included higher costs due to planned low production level of the animal...

2012-05-14 02:27:31

BEIJING, May 14, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, has appointed Mr. Danny Chung as Chief Financial Officer, effective immediately. Ms. Nan Wang, who has served as interim Chief Financial Officer since August 2011, will continue as the Company's Vice President. "Mr. Chung possesses the relevant experiences and credentials, which meet the Company's needs," said Dr. Weidong Yin, Chairman and CEO. "Beyond...

2012-05-08 02:28:20

BEIJING, May 8, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2012 before market on Tuesday, May 15, 2012. The Company will host a conference call on Tuesday, May 15, 2012 at 8:00 a.m. EDT (May 15, 2012 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate...

2012-04-12 02:38:18

BEIJING, April 12, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed its 2011 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2011 on April 12, 2012. The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section. The Company will provide a hard copy of its complete...

2012-04-12 02:38:16

BEIJING, April 12, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that management will attend the April 2012 Goldman Sachs/Gao Hua Healthcare Corporate Day in Hong Kong. Ms. Nan Wang, Interim Chief Financial Officer, and Ms. Helen Yang, Investor Relations Director, will be participating in one-on-one meetings on April 17, 2012. About Sinovac Sinovac Biotech Ltd. is a China-based biopharmaceutical...